PTCT•benzinga•
PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July
Summary
PTC Therapeutics presented new Phase 3 data on sepiapterin, showing potential benefits for PKU patients ahead of key regulatory decisions in 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 20, 2025 by benzinga